These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2555 related articles for article (PubMed ID: 26030518)
1. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. Turner NC; Ro J; André F; Loi S; Verma S; Iwata H; Harbeck N; Loibl S; Huang Bartlett C; Zhang K; Giorgetti C; Randolph S; Koehler M; Cristofanilli M; N Engl J Med; 2015 Jul; 373(3):209-19. PubMed ID: 26030518 [TBL] [Abstract][Full Text] [Related]
2. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results. Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278 [TBL] [Abstract][Full Text] [Related]
3. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. Turner NC; Slamon DJ; Ro J; Bondarenko I; Im SA; Masuda N; Colleoni M; DeMichele A; Loi S; Verma S; Iwata H; Harbeck N; Loibl S; André F; Puyana Theall K; Huang X; Giorgetti C; Huang Bartlett C; Cristofanilli M N Engl J Med; 2018 Nov; 379(20):1926-1936. PubMed ID: 30345905 [TBL] [Abstract][Full Text] [Related]
4. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Finn RS; Crown JP; Lang I; Boer K; Bondarenko IM; Kulyk SO; Ettl J; Patel R; Pinter T; Schmidt M; Shparyk Y; Thummala AR; Voytko NL; Fowst C; Huang X; Kim ST; Randolph S; Slamon DJ Lancet Oncol; 2015 Jan; 16(1):25-35. PubMed ID: 25524798 [TBL] [Abstract][Full Text] [Related]
5. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Cristofanilli M; Turner NC; Bondarenko I; Ro J; Im SA; Masuda N; Colleoni M; DeMichele A; Loi S; Verma S; Iwata H; Harbeck N; Zhang K; Theall KP; Jiang Y; Bartlett CH; Koehler M; Slamon D Lancet Oncol; 2016 Apr; 17(4):425-439. PubMed ID: 26947331 [TBL] [Abstract][Full Text] [Related]
6. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis. Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246 [TBL] [Abstract][Full Text] [Related]
7. Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3). Verma S; Bartlett CH; Schnell P; DeMichele AM; Loi S; Ro J; Colleoni M; Iwata H; Harbeck N; Cristofanilli M; Zhang K; Thiele A; Turner NC; Rugo HS Oncologist; 2016 Oct; 21(10):1165-1175. PubMed ID: 27368881 [TBL] [Abstract][Full Text] [Related]
8. Palbociclib and Letrozole in Advanced Breast Cancer. Finn RS; Martin M; Rugo HS; Jones S; Im SA; Gelmon K; Harbeck N; Lipatov ON; Walshe JM; Moulder S; Gauthier E; Lu DR; Randolph S; Diéras V; Slamon DJ N Engl J Med; 2016 Nov; 375(20):1925-1936. PubMed ID: 27959613 [TBL] [Abstract][Full Text] [Related]
9. FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. Walker AJ; Wedam S; Amiri-Kordestani L; Bloomquist E; Tang S; Sridhara R; Chen W; Palmby TR; Fourie Zirkelbach J; Fu W; Liu Q; Tilley A; Kim G; Kluetz PG; McKee AE; Pazdur R Clin Cancer Res; 2016 Oct; 22(20):4968-4972. PubMed ID: 27407089 [TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of CDK4/6 inhibitor plus endocrine therapy in HR-positive/HER2-0 and HER2-low-positive metastatic breast cancer: a secondary analysis of PALOMA-2 and PALOMA-3 trials. Li H; Wu Y; Zou H; Koner S; Plichta JK; Tolaney SM; Zhang J; He YW; Wei Q; Tang L; Zhang H; Zhang B; Guo Y; Chen X; Li K; Lian L; Ma F; Luo S EBioMedicine; 2024 Jul; 105():105186. PubMed ID: 38861871 [TBL] [Abstract][Full Text] [Related]
11. PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer. Mayer EL; Ren Y; Wagle N; Mahtani R; Ma C; DeMichele A; Cristofanilli M; Meisel J; Miller KD; Abdou Y; Riley EC; Qamar R; Sharma P; Reid S; Sinclair N; Faggen M; Block CC; Ko N; Partridge AH; Chen WY; DeMeo M; Attaya V; Okpoebo A; Alberti J; Liu Y; Gauthier E; Burstein HJ; Regan MM; Tolaney SM J Clin Oncol; 2024 Jun; 42(17):2050-2060. PubMed ID: 38513188 [TBL] [Abstract][Full Text] [Related]
12. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675 [TBL] [Abstract][Full Text] [Related]
13. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. Di Leo A; Johnston S; Lee KS; Ciruelos E; Lønning PE; Janni W; O'Regan R; Mouret-Reynier MA; Kalev D; Egle D; Csőszi T; Bordonaro R; Decker T; Tjan-Heijnen VCG; Blau S; Schirone A; Weber D; El-Hashimy M; Dharan B; Sellami D; Bachelot T Lancet Oncol; 2018 Jan; 19(1):87-100. PubMed ID: 29223745 [TBL] [Abstract][Full Text] [Related]
14. Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3. Cristofanilli M; DeMichele A; Giorgetti C; Turner NC; Slamon DJ; Im SA; Masuda N; Verma S; Loi S; Colleoni M; Theall KP; Huang X; Liu Y; Bartlett CH Eur J Cancer; 2018 Nov; 104():21-31. PubMed ID: 30308388 [TBL] [Abstract][Full Text] [Related]
15. Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer. Mangini NS; Wesolowski R; Ramaswamy B; Lustberg MB; Berger MJ Ann Pharmacother; 2015 Nov; 49(11):1252-60. PubMed ID: 26324355 [TBL] [Abstract][Full Text] [Related]
16. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. Sledge GW; Toi M; Neven P; Sohn J; Inoue K; Pivot X; Burdaeva O; Okera M; Masuda N; Kaufman PA; Koh H; Grischke EM; Frenzel M; Lin Y; Barriga S; Smith IC; Bourayou N; Llombart-Cussac A J Clin Oncol; 2017 Sep; 35(25):2875-2884. PubMed ID: 28580882 [TBL] [Abstract][Full Text] [Related]
17. Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer. Ham A; Kim MH; Kim GM; Kim JH; Kim JY; Park HS; Park S; Cho YU; Park BW; Kim SI; Sohn J Breast Cancer Res Treat; 2020 Aug; 183(1):107-116. PubMed ID: 32577940 [TBL] [Abstract][Full Text] [Related]
18. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women. Cersosimo RJ Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120 [TBL] [Abstract][Full Text] [Related]
19. Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients. Masuda N; Inoue K; Nakamura R; Rai Y; Mukai H; Ohno S; Hara F; Mori Y; Hashigaki S; Muramatsu Y; Nagasawa T; Umeyama Y; Huang X; Iwata H Int J Clin Oncol; 2019 Mar; 24(3):262-273. PubMed ID: 30392115 [TBL] [Abstract][Full Text] [Related]
20. Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study. Waller J; Mitra D; Mycock K; Taylor-Stokes G; Milligan G; Zhan L; Iyer S J Glob Oncol; 2019 May; 5():JGO1800239. PubMed ID: 31050919 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]